Patient reported respiratory symptoms and lung radiation doses 11 years after loco-regional breast cancer radiation therapy in the DBCG RT Nation Study
DOI:
https://doi.org/10.2340/1651-226X.2025.43973Keywords:
Adjuvant loco-regional radiation therapy, breast cancer, late effects, pulmonary late effectsAbstract
Background and purpose: The Danish Patient Association of Late Effects has received numerous inquiries from breast cancer (BC) survivors suspecting that adjuvant radiotherapy (RT) was the reason for respiratory symptoms. This study investigated patient-reported respiratory symptoms after locoregional RT and their association with ipsilateral lung radiation dose.
Patient/material and methods: Patient-reported outcomes (PROs) and RT plans from BC patients treated at a single institution over 2008–2016 were collected. PROs included dyspnoea (EORTC QLQ-C30), cough (PRO-CTCAE), smoking and comorbidities. RT dose-volume metrics were registered including ipsilateral mean lung dose (MLD), and volumes receiving 5 Gy (V5) and 20 Gy (V20). Patients were stratified into MLD tertiles (‘low’, ‘intermediate’, ‘high’) and compared. Additionally, responders were dichotomised by dyspnoea and cough scores (‘low’ vs ‘high’), and dose metrics were compared between symptom groups.
Results: Of 1,011 questionnaire distributed, 490 (49%) were completed and analysed. Median age was 65.8 years (interquartile range [IQR] 58.8;73.4), median time from RT to questionnaire was 11.1 years (IQR 8.9;13.2). Overall MLD was 12.9Gy (standard deviation [SD] 2.8). Any degree of dyspnoea was reported by 203 (41%) and any degree cough was reported by 175 (37%). No differences in dyspnoea/cough scores between MLD groups were found. MLD was 13.0Gy (SD 2.7) in the low dyspnoea group and 12.0Gy (SD 3.0) in the high dyspnoea group, (p = 0.04). MLD was 13.0 Gy (SD 2.7) in the low cough group and 12.5Gy (SD 3.1) in the high cough group (p = 0.23). The same pattern was found for V5lung and V20lung.
Interpretation: No associations between lung dose and patient-reported respiratory symptoms were found for node-positive BC patients 11 years after RT.
Downloads
References
Danish Breast Cancer Group. DBCG kvalitetsdatabase for Brystkraeft. 2024. [cited May 27th 2025] Available from: https://www.dbcg.dk/kvalitetsdatabasen/rapporter
Offersen BV, Alsner J, Nielsen H, Krause M, Stenbygaard L, Mjaaland I, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38:3615–25.
https://doi.org/10.1200/JCO.20.01363
Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Stenbygaard L, et al. Partial breast irradiation versus whole breast irradiation for early breast cancer patients in a randomized phase III trial: the Danish Breast Cancer Group partial breast irradiation trial. J Clin Oncol. 2022;40:4189–97.
https://doi.org/10.1200/JCO.22.00451
Thorsen LBJ, Thomsen MS, Berg M, Jensen I, Josipovic M, Overgaard M, et al. CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects. Acta Oncol. 2014;53(8):1027–34.
https://doi.org/10.3109/0284186X.2014.925579
Nielsen AWM, Thorsen LBJ, Özkan D, Matthiessen LW, Maae E, Milo MLH, et al. Internal mammary node irradiation in 4541 node-positive breast cancer patients treated with newer systemic therapies and 3D-based radiotherapy (DBCG IMN2): a prospective, nationwide, population-based cohort study. Lancet Reg. Health – Europe. 2025;49:101160.
https://doi.org/10.1016/j.lanepe.2024.101160
Leeuwen MV, Kieffer JM, Young TE, Annunziata MA, Arndt V, Arraras JI, et al. Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. J Cancer Surviv. 2023;17(4):1111–30.
https://doi.org/10.1007/s11764-021-01160-1
Karlsen J, Tandestad T, Steinshamn S, Salvesen Ø, Parlikar ND, Lundgren S, et al. Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2024;118(4):1066–77.
https://doi.org/10.1016/j.ijrobp.2023.10.026
Gueiderikh A, Sarrade T, Kirova Y, De La Lande B, Vathaire FD, Auzac G, et al. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Front Oncol. 2023;13:2–12.
De Rose F, De Santis MC, Lucidi S, Colciago RR, Marino L, Cucciarelli F, et al. Dose constraints in breast cancer radiotherapy. A critical review. Radiother Oncol. 2025;202:110591.
https://doi.org/10.1016/j.radonc.2024.110591
Ejlertsen B, Offersen BVO, Overgaard J, Christiansen P, Jensen MB, Kroman N, et al. Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration. Acta Oncol. 2018;57(1):3–12.
https://doi.org/10.1080/0284186X.2017.1408962
Refsgaard L, Buhl ES, Yates E, Maae E, Berg M, Al-Rawi S, et al. Evaluating Danish Breast Cancer Group locoregional radiotherapy guideline adherence in clinical treatment data 2008–2016: the DBCG RT Nation study. Radiother Oncol. 2024;199:110289.
https://doi.org/10.1016/j.radonc.2024.110289
The Danish Association of Late Effects. [cited May 27th 2025] Available from: www.senfoelger.dk
Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021;21(1):9.
https://doi.org/10.1186/s12890-020-01376-4
Meattini I, Guenzi M, Fozza A, Vidali C, Rovea P, Meacci F, et al. Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer. Breast Cancer. 2017;24(1):52–62.
https://doi.org/10.1007/s12282-016-0694-3
Käsmann L, Dietrich A, Staab-Weijnitz CA, Manapov F, Behr J, Rimner A, et al. Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol. 2020;15(1):214.
https://doi.org/10.1186/s13014-020-01654-9
Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol. 2015;114(1):56–65.
https://doi.org/10.1016/j.radonc.2014.10.004
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–8.
https://doi.org/10.1056/NEJMoa1209825
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
https://doi.org/10.1016/j.jbi.2008.08.010
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):165–376.
https://doi.org/10.1093/jnci/85.5.365
Juul T, Petersen MA, Holzner B, Laurberg S, Christensen P, Grønvold M. Danish population-based reference data for the EORTC QLQ-C30: associations with gender, age and morbidity. Qual Life Res. 2014;23(8):2183–93.
https://doi.org/10.1007/s11136-014-0675-y
Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the us national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015;1(8):1051–9.
https://doi.org/10.1001/jamaoncol.2015.2639
Bæksted C, Nissen A, Pappot H, Bidstrup PE, Mitchell SA, Basch E, et al. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Pain Symptom Manage. 2016;52(2):292–7.
https://doi.org/10.1016/j.jpainsymman.2016.02.008
Andersen K, Mouridsen H. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer. Acta Oncol. 1988;27(6A):627–47.
https://doi.org/10.3109/02841868809091763
Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. 2001, Brussels: European Organisation for Research and Treatment of Cancer
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
https://doi.org/10.1093/jnci/dju244
Refsgaard L, Buhl ES, Nielsen AWM, Thomsen MS, Andersen K, Jensen I, et al. Quality assurance of internal mammary node irradiation in the DBCG IMN2 study. Radiother Oncol. 2025;202:110600.
Refsgaard L, Milo MLH, Buhl ES, Jensen JM, Maae E, Berg M, et al. The effect of coronary artery calcifications and radiotherapy on the risk of coronary artery disease in high-risk breast cancer patients in the DBCG RT-Nation cohort. Radiother Oncol. 2025;204:110705.
https://doi.org/10.1016/j.radonc.2024.110705
Refsgaard L, Skarsø ER, Ravkilde T, Nissen HD, Olsen M, Boye K, et al. End-to-end framework for automated collection of large multicentre radiotherapy datasets demonstrated in a Danish Breast Cancer Group cohort. Phys Imaging Radiat Oncol. 2023;27:100485.
Skarsø ER, Refsgaard L, Saini A, Møller DS, Lorenzen EL, Maae E, et al. Development of a national deep learning-based auto-segmentation model for the heart on clinical delineations from the DBCG RT nation cohort. Acta Oncol. 2023;62(10):1201–7.
https://doi.org/10.1080/0284186X.2023.2252582
Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicic V, Jakobsen EH, et al. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncol. 2013;52(4):703–10.
https://doi.org/10.3109/0284186X.2013.765064
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol. 2015;114(1):3–10.
https://doi.org/10.1016/j.radonc.2014.11.030
Francolini G, Thomsen MS, Yates ES, Kirkove C, Jensen I, Blix ES, et al. Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1. Radiother Oncol. 2017;123(2):282–7.
https://doi.org/10.1016/j.radonc.2017.03.011
Thorsen LBJ, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34(4):314–20.
https://doi.org/10.1200/JCO.2015.63.6456
Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27.
https://doi.org/10.1056/NEJMoa1415369
Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–16.
https://doi.org/10.1056/NEJMoa1415340
de Boniface J, Filtenborg TT, Rydén L, Szulkin R, Reimer T, Kühn T, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024; 390(13):1163–75.
https://doi.org/10.1056/NEJMoa2313487
Pollard TJ, Johnson AEW, Raffa JD, Mark RG. TableOne: an open source Python package for producing summary statistics for research papers. JAMIA Open. 2018;1(1):26–31.
https://doi.org/10.1093/jamiaopen/ooy012
Løkke A, Fabricius PG, Vestbo J, Marott JL, Lange P. Prevalence of chronic obstructive pulmonary disease in Copenhagen. Results from The Copenhagen City Heart Study. Dan Med J. 2007;169(46):3956–60.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Maja Bendtsen Sharma, Lasse Hindhede Refsgaard, Elisabeth Bendstrup, Emma Skarsø Buhl, Robert Zachariae, Rasmus Blechingberg Friis, Ingeborg Farver-Vestergaard, Stine Sofia Korreman, Birgitte Vrou Offersen
This work is licensed under a Creative Commons Attribution 4.0 International License.
